Pipeline Horizon
A benchmarking dashboard for biotech R&D operations leads — see how your in-house candidates rank against IsoDDE, AlphaFold 3, and Boltz-2 on binding affinity and novel-pocket success so you know where to deploy AI next.
heads of computational chemistry and translational R&D at mid-sized biotechs
- Compare in-house candidate hit rates against public benchmark numbers
- Track novel-binding-pocket success rate per target across engines
- Cost and time-to-result table comparing physics-based FEP against AI engines
- Investor-ready compliance report showing your hit-rate versus industry
IsoDDE more than doubled AlphaFold 3's accuracy on novel pockets, so ops leads need a clear-eyed tool to decide where to deploy it before the hype cycle ends and budgets are committed.
HN 60 points plus headline pickup reflects strong industry interest; audience is niche but well-fundedPDF Accurate Predictions of Novel Biomolecular Interactions with IsoDDE ↗
Public benchmark code and papers exist but no business-facing dashboard productizes themPDF Accurate Predictions of Novel Biomolecular Interactions with IsoDDE ↗
Pharma ops teams have real budgets; $5-15k/mo per customer is realisticPDF Accurate Predictions of Novel Biomolecular Interactions with IsoDDE ↗
Drug discovery AI is a multi-decade enterprise need; switching costs are high once embedded
Hard: requires deep domain expertise, multiple benchmark integrations, and validation against customer pipelines